An association between antipsychotic An association between antipsychotic medication and diabetes mellitus and/or medication and diabetes mellitus and/or impaired glucose tolerance was reported impaired glucose tolerance was reported in the 1950s, soon after chlorpromazine in the 1950s, soon after chlorpromazine entered clinical practice (Hiles, 1956) . entered clinical practice (Hiles, 1956 ). Other reports followed (e.g. Cooperberg Other reports followed (e.g. Cooperberg & Eidlow, 1956 ). Although many of & Eidlow, 1956) . Although many of these reports had methodological shortthese reports had methodological shortcomings, by the late 1960s there was a comings, by the late 1960s there was a general acceptance that antipsychotic drugs general acceptance that antipsychotic drugs could cause diabetes, and the term 'phenocould cause diabetes, and the term 'phenothiazine diabetes' was coined (Thonnardthiazine diabetes' was coined (ThonnardNeumann, 1968) . There was little further Neumann, 1968) . There was little further interest in the subject until recently, when interest in the subject until recently, when attention became focused on the relationattention became focused on the relationship between the atypical antipsychotics, ship between the atypical antipsychotics, and impaired glucose tolerance and diaand impaired glucose tolerance and diabetes. In late 2003 the Food and Drug betes. In late 2003 the Food and Drug Administration (FDA) recommended upAdministration (FDA) recommended updated product labelling for all atypical dated product labelling for all atypical antipsychotics licensed in the USA, to inantipsychotics licensed in the USA, to include a warning about their association clude a warning about their association with hyperglycaemia and diabetes. with hyperglycaemia and diabetes.
Evidence for an association between Evidence for an association between antipsychotics and diabetes can be gleaned antipsychotics and diabetes can be gleaned from many sources, including prevalence from many sources, including prevalence studies, anecdotal reports, retrospective studies, anecdotal reports, retrospective case-note studies, pharmaco-epidemiologicase-note studies, pharmaco-epidemiological studies, 'physiological' studies assessing cal studies, 'physiological' studies assessing various parameters relevant to control of various parameters relevant to control of blood glucose, and prospective studies. blood glucose, and prospective studies. Prospective studies represent the highest Prospective studies represent the highest level of evidence and should carry the most level of evidence and should carry the most weight. Nevertheless, it is important to weight. Nevertheless, it is important to evaluate all sources of data when considerevaluate all sources of data when considering such an important issue. This paper ing such an important issue. This paper therefore provides a critical review of the therefore provides a critical review of the first four data sources listed above. Before first four data sources listed above. Before considering these data, it is important to considering these data, it is important to review risk factors for diabetes. review risk factors for diabetes.
Risk factors for diabetes Risk factors for diabetes
Socio-demographic and lifestyle factors Socio-demographic and lifestyle factors Any study that attempts to determine Any study that attempts to determine whether there is a causal relationship whether there is a causal relationship between antipsychotic medications and between antipsychotic medications and diabetes needs to account for the diabetes needs to account for the A recurrent problem with using non-A recurrent problem with using nonprospective data is that, by their very prospective data is that, by their very nature, such confounders are often ignored. nature, such confounders are often ignored.
Diabetes mellitus has a high prevalence Diabetes mellitus has a high prevalence rate in most Western countries, and this has rate in most Western countries, and this has increased dramatically in the past decade. increased dramatically in the past decade. In the UK, it has been estimated that apIn the UK, it has been estimated that approximately 1.4 million people have been proximately 1.4 million people have been diagnosed with diabetes and that a further diagnosed with diabetes and that a further 1 million people have the disorder but are 1 million people have the disorder but are undiagnosed (Bennett undiagnosed (Bennett et al et al, 1995) . Conse-, 1995) . Consequently, if diabetes is diagnosed for the quently, if diabetes is diagnosed for the first time during antipsychotic treatment, first time during antipsychotic treatment, a causal relationship cannot automatically a causal relationship cannot automatically be assumed; the diabetes might have be assumed; the diabetes might have existed prior to initiation of antipsychotic existed prior to initiation of antipsychotic treatment, but without being identified. treatment, but without being identified.
Schizophrenia Schizophrenia
Several studies from the pre-antipsychotic Several studies from the pre-antipsychotic era reported insulin resistance and abnormera reported insulin resistance and abnormalities of glucose homoeostasis in patients alities of glucose homoeostasis in patients with schizophrenia (e.g. Lorenz, 1922; Brawith schizophrenia (e.g. Lorenz, 1922; Braceland celand et al et al, 1946; Freeman, 1946) . Freeman, 1946) . This can be explained either in terms of an incan be explained either in terms of an intrinsic association between schizophrenia trinsic association between schizophrenia and impaired glucose tolerance, or as a reand impaired glucose tolerance, or as a result of aspects of lifestyle that are risk facsult of aspects of lifestyle that are risk factors for impaired glucose tolerance being tors for impaired glucose tolerance being more common in patients with schizomore common in patients with schizophrenia than in the general population. phrenia than in the general population. For example, patients with schizophrenia For example, patients with schizophrenia living in the community have been shown living in the community have been shown to exercise less, smoke more and have less to exercise less, smoke more and have less healthy diets than a control group (Brown healthy diets than a control group (Brown et al et al, 1999) .
, 1999). Ryan Ryan et al et al (2003) studied drug-naıve (2003) studied drug-naïve patients with first-episode schizophrenia, patients with first-episode schizophrenia, and so avoided the potential confounding and so avoided the potential confounding effect of antipsychotic medication. Of 26 effect of antipsychotic medication. Of 26 patients with first-episode schizophrenia, 4 patients with first-episode schizophrenia, 4 (15%) had impaired fasting glucose toler-(15%) had impaired fasting glucose tolerance, compared with none of a control ance, compared with none of a control s 8 0 s 8 0 et al, 1989) .
B R I T I S H J O UR N A L O F P SYC HI AT RY B R I T I S H J O UR N A L O F P S YC H I AT RY
, 1989). If schizophrenia is an independent If schizophrenia is an independent risk factor for diabetes mellitus, and at risk factor for diabetes mellitus, and at present this can only be regarded as a present this can only be regarded as a hypothesis, then it is possible that the hypothesis, then it is possible that the risk conferred may vary depending on the risk conferred may vary depending on the subtype of the illness, its duration and subtype of the illness, its duration and severity. severity.
METHOD METHOD
A Medline search was under-A Medline search was undertaken, supplemented by manual searches taken, supplemented by manual searches of journals and conference abstracts, to of journals and conference abstracts, to identify non-prospective studies. identify non-prospective studies.
RESULTS RESULTS

Prevalence studies Prevalence studies
Several studies have used a cross-sectional Several studies have used a cross-sectional design to determine the prevalence of design to determine the prevalence of diabetes, and in some cases impaired gludiabetes, and in some cases impaired glucose tolerance, in patients with schizocose tolerance, in patients with schizophrenia. When interpreting the results, phrenia. When interpreting the results, one needs to make comparisons with local one needs to make comparisons with local populations that are matched for age; the populations that are matched for age; the prevalence of diabetes in the general popuprevalence of diabetes in the general population increases markedly with age and lation increases markedly with age and varies between countries. A consistent findvaries between countries. A consistent finding across these studies is that the rates ing across these studies is that the rates of diabetes and impaired glucose tolerof diabetes and impaired glucose tolerance are higher than in the comparative ance are higher than in the comparative population. population.
Prior to the introduction of the atypical Prior to the introduction of the atypical antipsychotics, a study in Japan assessed antipsychotics, a study in Japan assessed 248 patients and reported a prevalence of 248 patients and reported a prevalence of type 2 diabetes of 8.8%, compared with type 2 diabetes of 8.8%, compared with 5% in a control group matched for age 5% in a control group matched for age and gender (Tabata and gender (Tabata et al et al, 1987) . In a US , 1987). In a US study (Dixon study (Dixon et al et al, 2000) , conducted in , 2000), conducted in 1994-1996, self-reported rates of diabetes 1994-1996, self-reported rates of diabetes in patients with schizophrenia were in patients with schizophrenia were 14.9% (lifetime) and 10.8% (current); in 14.9% (lifetime) and 10.8% (current); in contrast, the self-reported rate of diabetes contrast, the self-reported rate of diabetes in the general population of the USA in in the general population of the USA in 1994 was 1.2% for people aged 18-44 1994 was 1.2% for people aged 18-44 years and 6.3% for people aged 45-64 years and 6.3% for people aged 45-64 . In Italy, Mu- 2003) . Polypharmacy prevented , 2003) . Polypharmacy prevented these researchers from investigating these researchers from investigating whether rates differed in patients prescribed whether rates differed in patients prescribed different antipsychotics. However, none of different antipsychotics. However, none of the patients in this study had received an the patients in this study had received an atypical antipsychotic, either in the past or atypical antipsychotic, either in the past or at the time of the study. A study in London at the time of the study. A study in London has also shown that most cases of diabetes has also shown that most cases of diabetes and impaired glucose tolerance in inand impaired glucose tolerance in inpatients with schizophrenia are undiagpatients with schizophrenia are undiagnosed and are only revealed by blood nosed and are only revealed by blood glucose screening (Taylor glucose screening (Taylor et al et al, 2003) . , 2003). In summary, cross-sectional studies In summary, cross-sectional studies demonstrate that diabetes and impaired demonstrate that diabetes and impaired glucose tolerance are more prevalent in glucose tolerance are more prevalent in patients with schizophrenia than in the patients with schizophrenia than in the general population. It is also apparent that general population. It is also apparent that much of this morbidity is undiagnosed much of this morbidity is undiagnosed and is only revealed with systematic and is only revealed with systematic screening. Cross-sectional studies can only screening. Cross-sectional studies can only demonstrate associations, they cannot dedemonstrate associations, they cannot determine whether antipsychotic medication termine whether antipsychotic medication is a is a risk factor for diabetes or impaired risk factor for diabetes or impaired glucose tolerance. glucose tolerance.
Anecdotal reports Anecdotal reports
Anecdotal data regarding antipsychotic Anecdotal data regarding antipsychotic drugs and diabetes are available from spondrugs and diabetes are available from spontaneous adverse drug reaction reports, i.e. taneous adverse drug reaction reports, i.e. the 'yellow card' system in the UK and its the 'yellow card' system in the UK and its equivalent in other countries. However, equivalent in other countries. However, only a small fraction of adverse drug reaconly a small fraction of adverse drug reactions are reported in this way, and these tions are reported in this way, and these reports cannot be used to determine the inreports cannot be used to determine the incidence of an adverse reaction or to cidence of an adverse reaction or to compare rates between drugs. compare rates between drugs.
Published case reports are another Published case reports are another source of information, but they contain a source of information, but they contain a further element of bias as they depend on further element of bias as they depend on an individual clinician's interest in submitan individual clinician's interest in submitting a report, and on editorial selection ting a report, and on editorial selection policies. Despite their weaknesses, anecdopolicies. Despite their weaknesses, anecdotal reports are important, as they can be tal reports are important, as they can be the first indication of an adverse effect that the first indication of an adverse effect that was not identified in clinical trials. was not identified in clinical trials.
Conventional antipsychotics Conventional antipsychotics
In 1956, Hiles described five patients who In 1956, Hiles described five patients who developed hyperglycaemia and glycosuria developed hyperglycaemia and glycosuria soon after starting chlorpromazine, with resoon after starting chlorpromazine, with resolution on stopping the drug (Hiles, 1956) . solution on stopping the drug (Hiles, 1956) . A further five patients with well-controlled A further five patients with well-controlled diabetes were also described, in whom diadiabetes were also described, in whom diabetic control deteriorated after they were betic control deteriorated after they were prescribed chlorpromazine (Hiles, 1956) ; prescribed chlorpromazine (Hiles, 1956) ; in all five, diabetic control returned to its in all five, diabetic control returned to its pre-treatment level when chlorpromazine pre-treatment level when chlorpromazine was withdrawn. Other reports of similar rewas withdrawn. Other reports of similar reactions to chlorpromazine followed. For actions to chlorpromazine followed. For example, Cooperberg & Eidlow (1956) example, Cooperberg & Eidlow (1956) reported the case of a man with schizoreported the case of a man with schizophrenia who developed diabetes 12 days phrenia who developed diabetes 12 days after starting chlorpromazine. Thonnardafter starting chlorpromazine. ThonnardNeumann (1968) reported that the prevaNeumann (1968) reported that the prevalence of diabetes in psychiatric in-patients lence of diabetes in psychiatric in-patients had increased from 4.2% in 1954 to had increased from 4.2% in 1954 to 17.2% in 1966, and he attributed this to 17.2% in 1966, and he attributed this to the introduction of phenothiazines in the the introduction of phenothiazines in the intervening period. intervening period. 126 mg/dl (7 mmol/l) 126 mg/dl (7 mmol/l) or greater, a random or greater, a random glucose level of 200 mg/dl (11 mmol/l) or glucose level of 200 mg/dl (11 mmol/l) or greater, or elevated glycohaemoglobin greater, or elevated glycohaemoglobin values; and/or presence of metabolic acidvalues; and/or presence of metabolic acidosis or ketosis, and/or physician initiation osis or ketosis, and/or physician initiation of an antidiabetic drug. of an antidiabetic drug.
Atypical antipsychotics Atypical antipsychotics
The Koller data are summarised in The Koller data are summarised in Table 1 . For each of the four drugs Table 1 . For each of the four drugs assessed, the majority of reports occurred assessed, the majority of reports occurred within 6 months of the drug's first preswithin 6 months of the drug's first prescription and there was a spectrum of cription and there was a spectrum of reported abnormalities, including hyperreported abnormalities, including hyperglycaemia, diabetes, ketoacidosis and glycaemia, diabetes, ketoacidosis and hyperosmolar coma. For each drug, a hyperosmolar coma. For each drug, a number of fatalities were reported in number of fatalities were reported in association with hyperglycaemia. association with hyperglycaemia.
Hedenmalm Hedenmalm et al et al (2002) published an (2002) published an analysis of all reports suggestive of glucose analysis of all reports suggestive of glucose intolerance associated with risperidone, intolerance associated with risperidone, clozapine and olanzapine, identified in the clozapine and olanzapine, identified in the WHO database for adverse drug reactions. WHO database for adverse drug reactions. The analysis comprised reports of the The analysis comprised reports of the following diagnoses: glucose tolerance abfollowing diagnoses: glucose tolerance abnormal, hyperglycaemia, diabetes mellitus, normal, hyperglycaemia, diabetes mellitus, diabetes mellitus aggravated, ketosis, diadiabetes mellitus aggravated, ketosis, diabetic coma and glycosuria. Although pharbetic coma and glycosuria. Although pharmacovigilance studies cannot provide any macovigilance studies cannot provide any quantitative comparison of risk, they can quantitative comparison of risk, they can provide a qualitative description of the provide a qualitative description of the range of glucose abnormalities reported. range of glucose abnormalities reported. In the WHO data, each of the antipsychoIn the WHO data, each of the antipsychotics assessed was associated with the full tics assessed was associated with the full range of diagnoses ( Fig. 1) . range of diagnoses ( Fig. 1) .
Limitations of both the Koller and Limitations of both the Koller and WHO data include variation between re-WHO data include variation between reports in terms of the recording of risk facports in terms of the recording of risk factors for diabetes, and the fact that most tors for diabetes, and the fact that most reports had no good means of assessing reports had no good means of assessing causality. Furthermore, a reporting bias causality. Furthermore, a reporting bias cannot be excluded. Nevertheless, in both cannot be excluded. Nevertheless, in both data-sets the relatively young age of the padata-sets the relatively young age of the patients and the detection of most cases of tients and the detection of most cases of diabetes (where data on the temporal rediabetes (where data on the temporal relationship were available) within 6 months lationship were available) within 6 months of starting the antipsychotic medication of starting the antipsychotic medication suggest a causal relationship. In addition, suggest a causal relationship. In addition, within both data-sets and for each of the within both data-sets and for each of the antipsychotic medications investigated, antipsychotic medications investigated, there was a subset of patients in whom there was a subset of patients in whom the dosage of the antipsychotic was reduced the dosage of the antipsychotic was reduced or an alternative antipsychotic was preor an alternative antipsychotic was prescribed, and in a high proportion of these scribed, and in a high proportion of these patients, diabetic control improved or the patients, diabetic control improved or the diabetes resolved. A small group of patients diabetes resolved. A small group of patients were then challenged with the original antiwere then challenged with the original antipsychotic, and in the majority the psychotic, and in the majority the diabetes diabetes reappeared. Both patient sub reappeared. Both patient subsets provide sets provide further evidence that dia further evidence that diabetes may be betes may be caused by antipsychotic medications. caused by antipsychotic medications.
The literature review conducted for this The literature review conducted for this paper did not identify any published case paper did not identify any published case report of diabetes associated with amireport of diabetes associated with amisulpride. This may reflect the fact that sulpride. This may reflect the fact that amisulpride is not licensed in the USA; amisulpride is not licensed in the USA; alternatively, it may reflect a lower proalternatively, it may reflect a lower propensity for amisulpride to cause diabetes pensity for amisulpride to cause diabetes compared with other atypical antipsychocompared with other atypical antipsychotics. It is interesting to note that among tics. It is interesting to note that among the atypical antipsychotics, amisulpride the atypical antipsychotics, amisulpride has a distinct pharmacological profile, has a distinct pharmacological profile, being a pure dopamine D being a pure dopamine D 2 2 and D and D 3 3 receptor receptor antagonist. However, its diabetogenic antagonist. However, its diabetogenic potential remains to be confirmed -ideally potential remains to be confirmed -ideally in comparative prospective studies. Cerin comparative prospective studies. Certainly, adverse drug reaction reports of diatainly, adverse drug reaction reports of diabetes associated with amisulpride, and with betes associated with amisulpride, and with s 8 2 s 8 2 M:F, male/female ratio. M:F, male/female ratio. 1.The total number of cases exceeds the sum of the new-onset cases and the exacerbations because some cases could not be categorised. 1.The total number of cases exceeds the sum of the new-onset cases and the exacerbations because some cases could not be categorised. 2. Includes data provided in an addendum to the main paper. 2. Includes data provided in an addendum to the main paper. To be eligible for inclusion in the pine. To be eligible for inclusion in the study, patients had to be at least 18 years study, patients had to be at least 18 years old, have had a baseline weight measureold, have had a baseline weight measurement within 3 weeks of initiation of the ment within 3 weeks of initiation of the drug, a baseline fasting blood glucose drug, a baseline fasting blood glucose measurement within 3 months of initiation measurement within 3 months of initiation of the drug and a fasting blood glucose of the drug and a fasting blood glucose measurement after 1 year of treatment measurement after 1 year of treatment ( (+ +4 weeks). Patients who had received 4 weeks). Patients who had received more than 4 weeks' treatment with a more than 4 weeks' treatment with a second antipsychotic agent during the first second antipsychotic agent during the first year of treatment with olanzapine or risperyear of treatment with olanzapine or risperidone were excluded. From an initial idone were excluded. From an initial sample of 175 olanzapine-treated patients sample of 175 olanzapine-treated patients and 155 risperidoneand 155 risperidone-treated patients, 47 treated patients, 47 patients from each group fulfilled the patients from each group fulfilled the inclusion criteria. inclusion criteria.
At baseline, there was no significant At baseline, there was no significant difference between the risperidone-and difference between the risperidone-and olanzapine-treated patients in terms of olanzapine-treated patients in terms of body mass index (BMI), age or fasting body mass index (BMI), age or fasting blood glucose concentration. Over the 1-blood glucose concentration. Over the 1-year assessment period, the mean blood year assessment period, the mean blood glucose concentration increased signifiglucose concentration increased significantly within cantly within the olanzapine cohort the olanzapine cohort (+7.26 mg/dl), where (+7.26 mg/dl), whereas there was a nonas there was a nonsignificant increase in the risperidone cosignificant increase in the risperidone cohort (+0.68 mg/dl). One of the 94 patients hort (+0.68 mg/dl). One of the 94 patients developed diabetes during the study; this developed diabetes during the study; this patient had been treated with olanzapine. patient had been treated with olanzapine. Although the study shows that olanzapine Although the study shows that olanzapine was associated with a significantly greater was associated with a significantly greater increase in blood glucose concentrations increase in blood glucose concentrations than was risperidone, the mean blood than was risperidone, the mean blood glucose levels did not differ significantly glucose levels did not differ significantly between the two drug groups at follow-up. between the two drug groups at follow-up.
This study has several weaknesses. This study has several weaknesses. Many patients were excluded because their Many patients were excluded because their notes contained insufficient data, suggestnotes contained insufficient data, suggesting that the study might not have included ing that the study might not have included a representative sample population. The a representative sample population. The final sample population in the study was final sample population in the study was predominantly White and male. Also, it is predominantly White and male. Also, it is unclear in this study whether the two unclear in this study whether the two cohorts differed in terms of risk factors cohorts differed in terms of risk factors for diabetes (e.g. exercise level, diet and for diabetes (e.g. exercise level, diet and family history of diabetes). family history of diabetes).
Wirshing Wirshing et al et al (2002) conducted a study (2002) conducted a study with a similar design. In this study, patient with a similar design. In this study, patient notes were reviewed for 2.5 years before notes were reviewed for 2.5 years before and after starting treatment with a range and after starting treatment with a range of antipsychotic medications. A significant of antipsychotic medications. A significant increase in glucose levels was reported with increase in glucose levels was reported with olanzapine, clozapine and haloperidol, but olanzapine, clozapine and haloperidol, but not with quetiapine, risperidone or fluphennot with quetiapine, risperidone or fluphenazine. However, a large proportion of the azine. However, a large proportion of the initial patient sample was excluded because initial patient sample was excluded because the case notes did not contain enough data the case notes did not contain enough data to allow analysis, raising questions about to allow analysis, raising questions about how representative the final sample was. how representative the final sample was. Another weakness of this study was that Another weakness of this study was that it was unclear whether the blood glucose it was unclear whether the blood glucose levels recorded in the notes were fasting levels recorded in the notes were fasting samples or not. samples or not.
Yu
undertook a retrospective review of the psychiatric notes of 22 tive review of the psychiatric notes of 22 patients who had received a diagnosis of patients who had received a diagnosis of diabetes mellitus before beginning treatdiabetes mellitus before beginning treatment with olanzapine, risperidone or quement with olanzapine, risperidone or quetiapine. The authors reported that no tiapine. The authors reported that no antipsychotic medication was associated antipsychotic medication was associated with a worsening of blood glucose levels, with a worsening of blood glucose levels, although some treated with quetiapine or although some treated with quetiapine or risperidone required an increase in their risperidone required an increase in their dose of antidiabetic medication during the dose of antidiabetic medication during the study. Four of the 11 olanzapine-treated study. Four of the 11 olanzapine-treated patients showed a reduction in fasting patients showed a reduction in fasting blood glucose levels and a favourable modblood glucose levels and a favourable modification in their antidiabetic regimens durification in their antidiabetic regimens during the study. This study also has several ing the study. This study also has several weaknesses, including the small sample size weaknesses, including the small sample size and the short duration of treatment -the and the short duration of treatment -the mean duration of antipsychotic treatment mean duration of antipsychotic treatment was only 36.6 days. Most importantly, no was only 36.6 days. Most importantly, no information is given about the degree of information is given about the degree of diabetic control prior to the study. diabetic control prior to the study.
In summary, two retrospective caseIn summary, two retrospective casenote studies (Meyer, 2002 ; Wirshing note studies (Meyer, 2002; Wirshing et al et al, , 2002) have shown that several anti-2002) have shown that several antipsychotic medications (olanzapine, clozapsychotic medications (olanzapine, clozapine and haloperidol) are associated with pine and haloperidol) are associated with an increase in mean blood glucose levels an increase in mean blood glucose levels during treatment lasting 1 year or more. during treatment lasting 1 year or more. These studies cannot determine whether These studies cannot determine whether the increase was caused by the antithe increase was caused by the antipsychotic medication or by other factors. psychotic medication or by other factors. The lack of a significant increase in mean The lack of a significant increase in mean blood glucose concentration in one or more blood glucose concentration in one or more comparator groups treated with other anticomparator groups treated with other antipsychotic medications suggests a causal psychotic medications suggests a causal effect. However, this must remain speculaeffect. However, this must remain speculative, given that neither study adequately tive, given that neither study adequately controlled for risk factors for diabetes, controlled for risk factors for diabetes, and that the final samples might not have and that the final samples might not have been representative of the larger population been representative of the larger population of people with schizophrenia. of people with schizophrenia.
Pharmaco-epidemiological studies Pharmaco-epidemiological studies
A number of pharmaco-epidemiological A number of pharmaco-epidemiological studies investigating the association studies investigating the association between diabetes mellitus and antipsychotic between diabetes mellitus and antipsychotic medications have recently been published medications have recently been published or presented at conferences. Most of or presented at conferences. Most of these studies have been sponsored by the these studies have been sponsored by the pharmaceutical industry, and all rely on pharmaceutical industry, and all rely on the analysis of computerised databases of the analysis of computerised databases of patients treated in various organisations, patients treated in various organisations, and are limited by the quality of clinical and are limited by the quality of clinical data recorded. These studies compare the data recorded. These studies compare the risk of diabetes in cohorts of patients risk of diabetes in cohorts of patients treated with one or more atypical antipsytreated with one or more atypical antipsychotics with the risk in patients not taking chotics with the risk in patients not taking antipsychotics and/or using conventional antipsychotics and/or using conventional antipsychotics. Pharmaco-epidemiological antipsychotics. Pharmaco-epidemiological studies can be cross-sectional in design studies can be cross-sectional in design and determine prevalence rates of diabetes and determine prevalence rates of diabetes (e.g. Sernyak (e.g. Sernyak et al et al, 2002) , but most assess , 2002), but most assess the risk of new cases of diabetes appearing the risk of new cases of diabetes appearing during a specified observation period -i.e. during a specified observation period -i.e. they assess incidence rates. Before conthey assess incidence rates. Before considering the results of these studies, it is sidering the results of these studies, it is important to highlight their strengths and important to highlight their strengths and weaknesses. weaknesses.
Methodological issues Methodological issues
Pharmaco-epidemiological studies include Pharmaco-epidemiological studies include large samples of 'real patients' who may large samples of 'real patients' who may be more susceptible to developing diabetes be more susceptible to developing diabetes than the carefully selected patients who enthan the carefully selected patients who enter clinical trials. However, the pharmacoter clinical trials. However, the pharmacoepidemiological approach has four main epidemiological approach has four main weaknesses: weaknesses:
(a) (a) lack of standardisation with regard to lack of standardisation with regard to the detection and diagnosis of diabetes; the detection and diagnosis of diabetes; (2003) used the prescription of antidiabetic medication as a proxy for the diagdiabetic medication as a proxy for the diagnosis, thereby excluding all patients with nosis, thereby excluding all patients with the condition whose treatment involved the condition whose treatment involved dietary and lifestyle changes only. In addidietary and lifestyle changes only. In addition, without systematic screening of blood tion, without systematic screening of blood glucose levels in all patients, many cases glucose levels in all patients, many cases of diabetes are likely to be missed, and the of diabetes are likely to be missed, and the results could be distorted through differenresults could be distorted through differential detection as a result of variations in tial detection as a result of variations in screening (Citrome, 2003) . screening (Citrome, 2003) .
The second weakness of the pharmacoThe second weakness of the pharmacoepidemiological approach is that many such epidemiological approach is that many such studies fail to account for risk factors studies fail to account for risk factors associated with diabetes such as diet, exerassociated with diabetes such as diet, exercise level, smoking status, race, family cise level, smoking status, race, family history of the disorder, and BMI. In most history of the disorder, and BMI. In most of these studies it has been impossible to of these studies it has been impossible to control for these confounders, as the inforcontrol for these confounders, as the information required is not available within the mation required is not available within the database. database.
The third weakness is that pharmacoThe third weakness is that pharmacoepidemiological data are not available for epidemiological data are not available for all the atypical antipsychotic agents. Most all the atypical antipsychotic agents. Most of these studies have been conducted in of these studies have been conducted in the USA, and so exclude amisulpride and the USA, and so exclude amisulpride and zotepine because these drugs are not zotepine because these drugs are not licensed there. Several studies have exlicensed there. Several studies have excluded quetiapine and ziprasidone owing cluded quetiapine and ziprasidone owing to the small numbers of patients receiving to the small numbers of patients receiving these treatments at the time the data were these treatments at the time the data were collected. collected.
Finally, these studies do not control for Finally, these studies do not control for key aspects of the patients' psychiatric illkey aspects of the patients' psychiatric illness and antipsychotic treatment. For exness and antipsychotic treatment. For example, Koro ample, Koro et al et al (2002) assessed patients (2002) assessed patients over a 3-month period, but it is unclear over a 3-month period, but it is unclear how long patients had been receiving the how long patients had been receiving the specified class of antipsychotic prior to this. specified class of antipsychotic prior to this. As already discussed, there is evidence that As already discussed, there is evidence that schizophrenia may be an independent risk schizophrenia may be an independent risk factor for diabetes, yet none of the studies factor for diabetes, yet none of the studies reviewed controlled for length or severity reviewed controlled for length or severity of schizophrenia. Indeed, some studies were of schizophrenia. Indeed, some studies were not restricted to patients with schizonot restricted to patients with schizophrenia, but included all patients prescribed phrenia, but included all patients prescribed antipsychotic medications, irrespective of antipsychotic medications, irrespective of psychiatric diagnosis. psychiatric diagnosis. Tables 2 and 3 summarise the results of  Tables 2 and 3 summarise the results of the pharmaco-epidemiological studies pubthe pharmaco-epidemiological studies published or presented at conferences to date. lished or presented at conferences to date. Although the results are conflicting, two Although the results are conflicting, two themes emerge. Most studies report a highthemes emerge. Most studies report a higher risk of diabetes developing in patients er risk of diabetes developing in patients treated with antipsychotics compared with treated with antipsychotics compared with those who are not ( One of the best pharmaco-epidemioOne of the best pharmaco-epidemiological studies from a methodological perslogical studies from a methodological perspective is that by Cunningham pective is that by Cunningham et al et al (2003) . (2003). This study has not yet been published in This study has not yet been published in full, so its findings must be interpreted with full, so its findings must be interpreted with caution. Nevertheless, the study had the caution. Nevertheless, the study had the advantage of being independent of pharmaadvantage of being independent of pharmaceutical industry sponsorship, and the data ceutical industry sponsorship, and the data are adjusted for several important diabetes are adjusted for several important diabetes risk factors, including age, race and the risk factors, including age, race and the use of other diabetogenic drugs. The study use of other diabetogenic drugs. The study s 8 4 s 8 4 found that olanzapine, quetiapine and found that olanzapine, quetiapine and risperidone were all associated with a risperidone were all associated with a similarly increased risk of diabetes comsimilarly increased risk of diabetes compared with conventional antipsychotics, pared with conventional antipsychotics, although in the case of quetiapine this did although in the case of quetiapine this did not reach statistical significance -possibly not reach statistical significance -possibly owing to the smaller sample size. With all owing to the smaller sample size. With all three drugs, the hazard ratio was approxithree drugs, the hazard ratio was approximately 1.5 compared with conventional mately 1.5 compared with conventional antipsychotics.
Pharmaco-epidemiological study results Pharmaco-epidemiological study results
antipsychotics.
In the above study and in that by In the above study and in that by Sernyak Sernyak et al et al (2002) , the increased risk (2002), the increased risk of diabetes in users of atypical of diabetes in users of atypical v v. con-. conventional drugs was only apparent in ventional drugs was only apparent in younger age groups. This suggests that if younger age groups. This suggests that if atypical drugs are a causal factor in atypical drugs are a causal factor in younger age groups then they may be younger age groups then they may be bringing forward the presentation of bringing forward the presentation of an underlying diathesis rather than an underlying diathesis rather than precipitating diabetes precipitating diabetes de novo de novo. . Pharmaco-epidemiological studies can Pharmaco-epidemiological studies can only show an association; they cannot only show an association; they cannot prove causality. Thus, the higher rate of prove causality. Thus, the higher rate of diabetes seen in antipsychotic users comdiabetes seen in antipsychotic users compared with non-users may represent a caupared with non-users may represent a causal effect of the drugs, but other sal effect of the drugs, but other explanations must also be considered, inexplanations must also be considered, including the possible effect of schizophrenia cluding the possible effect of schizophrenia itself, the possibility that some patients reitself, the possibility that some patients receiving antipsychotic medications are more ceiving antipsychotic medications are more likely to have blood tests that detect dialikely to have blood tests that detect diabetes than patients who are not taking these betes than patients who are not taking these drugs, and the possibility that those using drugs, and the possibility that those using antipsychotics may have more risk factors antipsychotics may have more risk factors for diabetes, such as poor diet, lack of exerfor diabetes, such as poor diet, lack of exercise and obesity. Similarly, the higher rates cise and obesity. Similarly, the higher rates of diabetes seen in patients receiving atypiof diabetes seen in patients receiving atypical rather than conventional antipsychotics cal rather than conventional antipsychotics may represent a true differential effect of may represent a true differential effect of the medications in their ability to cause the medications in their ability to cause diabetes, but alternatively may represent diabetes, but alternatively may represent differential screening for diabetes and/or differential screening for diabetes and/or differential loading of risk factors among differential loading of risk factors among users of different classes of antipsychotic. users of different classes of antipsychotic.
The question of whether individual The question of whether individual atypical antipsychotic agents differ in their atypical antipsychotic agents differ in their propensity to cause diabetes is important, propensity to cause diabetes is important, but owing to their methodological weakbut owing to their methodological weaknesses, pharmaco-epidemiological studies nesses, pharmaco-epidemiological studies cannot provide a definitive answer. Most cannot provide a definitive answer. Most of the studies in Tables 2 and 3 did not have  of the studies in Tables 2 and 3 did not have the power to compare the relative risk of the power to compare the relative risk of diabetes between individual atypical drugs. diabetes between individual atypical drugs. Of those that did, the results are conflictOf those that did, the results are conflicting. For example, Fuller ing. For example, Fuller et al et al (2003) found (2003) found that olanzapine was associated with an inthat olanzapine was associated with an increased risk of developing diabetes comcreased risk of developing diabetes compared with risperidone, whereas Buse pared with risperidone, whereas Buse et al et al (2003) found no significant difference (2003) found no significant difference between these two drugs. between these two drugs.
DISCUSSION DISCUSSION
Diabetes mellitus is a common and freDiabetes mellitus is a common and frequently undiagnosed condition for which quently undiagnosed condition for which there are many risk factors, possibly includthere are many risk factors, possibly including schizophrenia itself. An association ing schizophrenia itself. An association between antipsychotic drugs and diabetes between antipsychotic drugs and diabetes was first suggested in the 1950s, but recent was first suggested in the 1950s, but recent interest has focused primarily on the atypiinterest has focused primarily on the atypical antipsychotics. Much of the available cal antipsychotics. Much of the available data are non-prospective, and, owing to data are non-prospective, and, owing to various methodological weaknesses, only various methodological weaknesses, only limited conclusions can be drawn. limited conclusions can be drawn.
Cross-sectional studies show that the Cross-sectional studies show that the prevalence of diabetes and impaired glucose prevalence of diabetes and impaired glucose tolerance among patients with schizotolerance among patients with schizophrenia is higher than in comparative popuphrenia is higher than in comparative populations, and that much of this morbidity is lations, and that much of this morbidity is undiagnosed. For several antipsychotic undiagnosed. For several antipsychotic agents (e.g. chlorpromazine, clozapine, agents (e.g. chlorpromazine, clozapine, olanzapine, risperidone and quetiapine) a olanzapine, risperidone and quetiapine) a subset of anecdotal reports describe diasubset of anecdotal reports describe diabetes appearing soon after the patient starts betes appearing soon after the patient starts taking the drug, resolving on stopping it, taking the drug, resolving on stopping it, and in some cases reappearing with a and in some cases reappearing with a further drug challenge. These cases indicate further drug challenge. These cases indicate that antipsychotics can cause diabetes in that antipsychotics can cause diabetes in some patients, but they cannot determine some patients, but they cannot determine the incidence or whether the risk varies betthe incidence or whether the risk varies between different antipsychotics. Some retroween different antipsychotics. Some retrospective case-note studies have shown a spective case-note studies have shown a significant increase in blood glucose levels significant increase in blood glucose levels during treatment with several antipsychotic during treatment with several antipsychotic medications (e.g. olanzapine, haloperidol medications (e.g. olanzapine, haloperidol and clozapine), but one cannot assume that and clozapine), but one cannot assume that this represents a causal relationship. this represents a causal relationship.
Pharmaco-epidemiological studies have Pharmaco-epidemiological studies have the advantage of assessing large cohorts of the advantage of assessing large cohorts of patients, but there is no standardisation in patients, but there is no standardisation in terms of detection and diagnosis of terms of detection and diagnosis of diabetes, and many risk factors are not diabetes, and many risk factors are not controlled for. Fairly consistent findings controlled for. Fairly consistent findings across these studies are a higher rate of across these studies are a higher rate of diabetes in patients receiving atypical diabetes in patients receiving atypical antipsychotic medications compared with antipsychotic medications compared with those those not receiving antipsychotics or not receiving antipsychotics or compared with those receiving convencompared with those receiving conventional agents. Studies attempting to estabtional agents. Studies attempting to establish whether the association with diabetes lish whether the association with diabetes varies between atypical antipsychotic medivaries between atypical antipsychotic medications are contradictory and inconclusive. cations are contradictory and inconclusive.
In summary, non-prospective studies In summary, non-prospective studies suggest that both conventional and atypical suggest that both conventional and atypical antipsychotic medications can cause diaantipsychotic medications can cause diabetes mellitus in some patients. Patients betes mellitus in some patients. Patients and clinicians need to be aware of this risk. and clinicians need to be aware of this risk. However, retrospective studies cannot However, retrospective studies cannot quantify this risk or determine whether it quantify this risk or determine whether it varies between drugs and how it compares varies between drugs and how it compares with recognised risk factors such as race, with recognised risk factors such as race, increasing age and obesity. These are increasing age and obesity. These are important clinical questions, but they can important clinical questions, but they can only be answered by well-designed prospeconly be answered by well-designed prospective studies that take account of potential tive studies that take account of potential confounders. confounders.
Dixon, L.,Weiden, P., Delahany, J., Dixon, L., Weiden, P., Delahany, J., et al et al ( Mukherjee, S., Decina, P., Bocola,V., Mukherjee, S., Decina, P., Bocola,V., et al et al (1996) (1996) Diabetes mellitus in schizophrenic patients. Diabetes mellitus in schizophrenic patients. Cross-sectional studies indicate that the prevalence of diabetes mellitus and impaired glucose tolerance is higher in patients with schizophrenia than in the general impaired glucose tolerance is higher in patients with schizophrenia than in the general population, with much of this morbidity being undiagnosed. population, with much of this morbidity being undiagnosed. & & Non-prospective studies suggest that both conventional and atypical antipsychotic Non-prospective studies suggest that both conventional and atypical antipsychotic medications can cause diabetes in some individuals. medications can cause diabetes in some individuals.
& & Atypical antipsychotic agents appear to increase the risk of diabetes more than Atypical antipsychotic agents appear to increase the risk of diabetes more than conventional antipsychotics do, but differential loading of risk factors for diabetes conventional antipsychotics do, but differential loading of risk factors for diabetes between these two groups and/or more intensive screening with atypical agents may between these two groups and/or more intensive screening with atypical agents may account for these differences. account for these differences. Retrospective studies can only establish an association between antipsychotic medications and diabetes; they cannot establish causality. medications and diabetes; they cannot establish causality.
& & Well-designed prospective studies are needed to quantify the risk associated with Well-designed prospective studies are needed to quantify the risk associated with antipsychotic medications, to determine whether the risk varies between agents, and antipsychotic medications, to determine whether the risk varies between agents, and how it compares with other recognised risk factors for diabetes. how it compares with other recognised risk factors for diabetes.
